Kausik Datta

Kausik Datta
Johns Hopkins Medicine | JHUSOM · Department of Medicine

M.Sc., Ph.D. M.A.

About

52
Publications
4,435
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
1,342
Citations
Introduction
Kausik Datta currently works at the School of Medicine, Johns Hopkins University. Kausik does research in immunology of host-fungal pathogen interaction, and immunodiagnostics.
Additional affiliations
September 2014 - present
Johns Hopkins Medicine
Position
  • Senior Research Specialist
September 2008 - September 2014
Johns Hopkins Medicine
Position
  • PostDoc Position
January 2008 - August 2008
Oregon Health and Science University
Position
  • PostDoc Position
Education
January 1997 - July 2004
All India Institute of Medical Sciences
Field of study
  • Microbiology
August 1994 - July 1996
Jawaharlal Nehru University
Field of study
  • Life Sciences
August 1991 - June 1994
University of Calcutta
Field of study
  • Physiology (Honors)

Publications

Publications (52)
Article
The fungal pathogen Pneumocystis jirovecii causes Pneumocystis pneumonia. Although the mitochondrial large subunit rRNA gene (mtLSU) is commonly used as a PCR target, a mitochondrial small subunit rRNA gene (mtSSU)–targeted MultiCode PCR assay was developed on the fully automated ARIES platform for detection of P. jirovecii in bronchoalveolar lavag...
Article
Aspergillosis complicating severe influenza infection has been increasingly detected worldwide. Recently, coronavirus disease-associated pulmonary aspergillosis (CAPA) has been detected through rapid reports, primarily from centers in Europe. We provide a case series of CAPA, adding 20 cases to the literature, with review of pathophysiology, diagno...
Article
Full-text available
Background: Liver tumours observed in rats exposed to micafungin led to a black box warning upon approval in Europe in 2008. Micafungin's risk for liver carcinogenicity in humans has not been investigated. We sought to describe the risk of fatal hepatocellular carcinoma (HCC) among persons who received micafungin and other parenteral antifungals (...
Article
Background: Cryptococcosis is increasingly recognized in people without HIV. Methods: A multicenter, prospective cohort study was performed in 25 U.S. centers. Consenting patients were prospectively followed for up to 2 years. Neurologic morbidities were assessed with longitudinal event depiction and functional scores (Montreal Cognitive Assessm...
Article
Background Establishing rapid diagnoses of invasive aspergillosis (IA) is priority, given poor outcomes of late therapy. Non-culture based tests that detect galactomannan and β-D glucan are available, but are technically cumbersome and rely on invasive sampling (blood or bronchoalveolar lavage). Methods We optimized a lateral flow dipstick assay u...
Chapter
Humans regularly interact with fungi, but these interactions rarely result in disease in persons with normal immunity. In contrast, persons with immune impairment are at high risk for fungal disease. The recognition that impaired immunity is central to the pathogenesis of many fungal diseases and that antifungal agents are often ineffective in the...
Article
Background Although echinocandins are generally well tolerated, there is little information on the frequency with which renal and hepatic adverse effects occur during use of micafungin or other parenteral antifungal (PAF) agents in clinical practice. Methods MYCOS is a multicentre cohort study of adult and paediatric patients who received micafung...
Article
Fungal organisms are ubiquitous in the environment. Pathogenic fungi, although relatively few in the whole gamut of microbial pathogens, are able to cause disease with varying degrees of severity in individuals with normal or impaired immunity. The disease state is an outcome of the fungal pathogen's interactions with the host immunity, and therefo...
Article
Full-text available
The mouse is now the primary animal used to model a variety of lung diseases. To study the mechanisms that underlie such pathologies, phenotypic methods are needed that can quantify the pathologic changes. Furthermore, to provide translational relevance to the mouse models, such measurements should be tests that can easily be done in both humans an...
Article
The role of B cells and antibody-mediated immunity (AMI) is poorly understood regarding infections with the encapsulated yeast species, Cryptococcus. Human cryptococcal disease, or cryptococcosis, generally occurs in the setting of immune suppression, including deficits of T cells and other components of cell-mediated immunity (CMI), as observed in...
Conference Paper
Background: Histoplasmosis is the most common endemic mycosis in the US. Infection is often mild in healthy individuals, in part due to effective interferon-gamma (INFγ) Th1 immune response. In those with immune suppression (organ transplantation or TNFa inhibition), reactivation infection can be severe or fatal. We hypothesize that development of...
Article
Full-text available
Specialized Candida albicans cell surface proteins called adhesins mediate binding of the fungus to host cells. The mammalian transglutaminase (TG) substrate and adhesin, Hyphal wall protein 1 (Hwp1), is expressed on the hyphal form of C. albicans where it mediates fungal adhesion to epithelial cells. Hwp1 is also required for biofilm formation and...
Article
Full-text available
Isavuconazole is an extended-spectrum triazole with in vitro activity against a wide variety of fungal pathogens. Clinical isolates of molds Aspergillus lentulus and Neosartorya udagawae and yeast Cryptococcus gattii VGII (implicated in the outbreak in the Pacific Northwest, North America) exhibit reduced susceptibilities to several azoles but high...
Article
Full-text available
Mortality associated with invasive aspergillosis (IA) remains high, partly because of delayed diagnosis. Detection of microbial exoantigens, released in serum and other body fluids during infection, may help timely diagnosis. In course of IA, Aspergillus galactomannan (GM), a well established polysaccharide biomarker, is released in body fluids inc...
Data
Details of Enzyme-linked immunosorbent assays (ELISAs). (DOCX)
Data
The putative urine inhibitor is a small (<2K Da), non-protein molecule, not affected by pH. A, Desalted or dialyzed urine at different MWCOs (40 KDa, 7 KDa, 3.5 KDa and 2 KDa), used as EPA293 diluent in sELISA, all improved signal similarly compared to untreated urine. B, Boiling and centrifugation (B/C), acidification (pH = 5.0), alkalinization (p...
Data
Details of fungal strains and exoantigen preparations. (DOCX)
Data
Additional observations on the nature of putative urine inhibitor. (DOCX)
Data
Urine negatively impacts antigen-MAb476 interaction in immunoassays. A, Incubation of MAb476-coated wells with urine or blocking buffer, followed by washing, prior to antigen addition; no diminution of signal: urine likely did not affect immobilized MAb476; B, Incubation of MAb476 in urine or PBS, followed by desalting, prior to indirect ELISA on E...
Data
Details of development of the lateral flow immunochromatographic assay. (DOCX)
Article
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) alter epithelial cell (EC) interactions with multiple microbes, such that dysregulated inflammation and injury occur with airway colonization in people with cystic fibrosis (CF). Aspergillus fumigatus frequently colonizes CF airways, but it has been assumed to be an innocen...
Article
Full-text available
The importance of T cell-mediated immunity for resistance to the disease (cryptococcal disease) caused by Cryptococcus neoformans is incontrovertible, but whether Ab immunity also contributes to resistance remains uncertain. To investigate the role of IgM in resistance to C. neoformans, we compared the survival, fungal burden, lung and brain inflam...
Article
Full-text available
Cryptococcus neoformans causes severe, and often fatal, disease (cryptococcosis) in immunocompromised patients, particularly in those with HIV/AIDS. Although resistance to cryptococcosis requires intact T-cell immunity, a possible role for antibody/B cells in protection against natural disease has not been definitively established. Previous studies...
Article
Full-text available
Cryptococcus gattii has emerged as a human and animal pathogen in the Pacific Northwest. First recognized on Vancouver Island, British Columbia, Canada, it now involves mainland British Columbia, and Washington and Oregon in the United States. In Canada, the incidence of disease has been one of the highest worldwide. In the United States, lack of c...
Article
A unique case of disseminated candidosis in premature twins is presented where twin A developed disease soon after birth and died prior to the administration of antifungal therapy. On the other hand, twin B developed infection on the 26th day of birth but survived, though with sequelae (hydrocephalus), since he was promptly and accurately diagnosed...
Article
Full-text available
The relatively uncommon fungal pathogen Cryptococcus gattii recently emerged as a significant cause of cryptococcal disease in human and animals in the Pacific Northwest of North America. Although genetic studies indicated its possible presence in the Pacific Northwest for more than 30 years, C. gattii as an etiological agent was largely unknown in...
Article
Full-text available
Vaccination with P13, a peptide mimotope of the cryptococcal capsular polysaccharide glucuronoxylomannan (GXM), has been shown to confer protection against a subsequent lethal Cryptococcus neoformans challenge. In this study, we sought to investigate whether P13-based vaccines could be effective in an already-established infection. To address this...
Article
In the Damage-response framework of microbial pathogenesis, infectious diseases are one outcome of a host-microorganism interaction in a susceptible host. In cryptococcal disease, damage to the host is caused by Cryptococcus neoformans virulence determinants, the nature of the host response, or both. Further, the disease may be acute or reactivated...
Article
The efficacy of antibody mediated immunity against Cryptococcus neoformans has not been established experimentally for human antibodies. Our group has previously shown that immunization with a conjugate consisting of a peptide mimotope of the C. neoformans capsular polysaccharide glucuronoxylomannan (GXM), P13, and diphtheria toxoid (P13-DT) prolon...
Article
Full-text available
The features of protective murine antibodies to the Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) have been rigorously investigated; however, the characteristics of protective human antibodies to GXM have not been defined. We produced monoclonal antibodies (MAbs) from XenoMouse mice (transgenic mice that express human im...
Article
The prevalence of specific serotypes of Cryptococcus neoformans in a given area bears on regional epidemiological patterns, the expected spectrum of clinical disease, and predicted response to therapy. In this retrospective study we analyzed the serotypes of 45 degrees C neoformans isolates from 36 North Indian patients with varied clinical present...
Article
Full-text available
Peptide mimotopes of capsular polysaccharides have been proposed as antigens for vaccines against encapsulated pathogens. In this study, we determined the antibody response to and efficacy of P13, a peptide mimetic of the Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM), in mice that produce human antibodies. P13 was conjug...
Article
In cryptococcosis, fluconazole is a standard prophylactic, therapeutic and maintenance option, particularly in the expanding HIV/AIDS group. However, its excessive use may lead to resistance in Cryptococcus neoformans. Variations in clinical response to fluconazole have already been noted elsewhere, and cases of post-therapy relapse are not uncommo...
Poster
RBx 7445 and RBx 7635: novel triazoles with potent broad-spectrum antifungal activity,
Poster
Full-text available
Thiotriazolones: A new class of potent antifungal agents
Article
The menace of cryptococcosis has assumed global proportions over the years. The tropical climate of the Indian subcontinent offers a suitable environment for Cryptococcus neoformans, and the onslaught of the acquired immune deficiency syndrome (AIDS) pandemic since the early 1990s has substantially influenced the situation. Coupled with that are th...
Article
Non- C. albicans Candida species are increasingly being recognized as the cause of vulvo-vaginal candidiasis. These species are often less susceptible to antifungal agents. Patients with diabetes mellitus are at risk for vulvo-vaginal candidasis. We assessed the species-specific prevalence rate and risk of candidiasis in patients with diabetes mell...
Article
A unique case of disseminated candidosis in premature twins is presented where twin A developed disease soon after birth and died prior to the administration of antifungal therapy. On the other hand, twin B developed infection on the 26th day of birth but survived, though with sequelae (hydrocephalus), since he was promptly and accurately diagnosed...

Questions

Question (1)
Question
I am looking for a comparative assessment of good quality ELISA-based kits available in the market for the detection of human IFN-gamma. I have used the Life Technologies/Pierce kit, and was very disappointed by their plate-to-plate variability and lack of consistency. 

Projects

Projects (3)
Archived project
To identify novel Azole derivatives as antifungal agents